17
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Bronquiolitis en neonatos: Experiencia de cuatro años en un hospital pediátrico de referencia nacional Translated title: Bronchiolitis in neonates: A four-year experience in a Pediatric Hospital that is a national reference

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introducción: la bronquiolitis es causa importante de morbimortalidad en pediatría motivo frecuente de consulta e ingreso hospitalario en meses invernales. Objetivo: describir epidemiología etiología evolución y tratamientos realizados en recién nacidos ingresados por bronquiolitisentre los años 2010 a 2013. Material y métodos: descriptivo retrospectivo. Se incluyeron todos los recién nacidos ingresados por bronquiolitis. Variables: edad gestacional sexo comorbilidades antecedentes ambientales agente etiológico días de internación insuficiencia respiratoria oxigeno de alto flujo ingreso a cuidados intensivos ventilación mecánica muerte. Resultados: ingresaron 226 neonatos 51 3 varones promedio de internación de 6 5 días. Conviviente con infección respiratoria 75 2 tabaquismo 28 3 cardiopatía congénita 9 7 pretérmino 7 9 . Se aisló virus respiratorio sincicial en 59 5 . Recibieron oxígeno de alto flujo 9 7 . Ingresaron a cuidados intensivos 11 5 apoyo ventilatorio mecánico 34 6 de los mismos. No se registraron muertes. Conclusiones: el número de ingresos de recién nacidos por bronquiolitis no es despreciable. El virus respiratorio sincicial es el agente etiológico más identificado y el causante de mayor número de ingresos a cuidados intensivos. No se constataron fallecimientos.

          Translated abstract

          Introduction: bronchiolitis is the leading cause of morbidity and mortality in children a frequent cause of consultation and hospitalization in winter months. Objective: to describe epidemiology etiology evolution and treatments applied to infants hospitalized for bronchiolitis between 2010 and 2013. Methods: descriptive retrospective study. All newborns hospitalized for bronchiolitis were included in the study. Variables: gestational age sex comorbidities environmental history etiologic agent days of hospitalization respiratory failure high-flow oxygen admission to intensive care mechanical ventilation death. Results: 226 neonates were admitted 51.3 of them were male average hospital stay was 6.5 days. 75.2 domestic partners had respiratory infections 28.3 smoked 9.7 presented congenital heart disease and 7.9 were preterm. Respiratory syncytial virus was isolated in 59.5 . 9.7 received high-flow oxygen. 11.5 were admitted to intensive care 34.6 of the latter needed mechanical ventilatory support. No deaths were reported. Conclusions: the number of hospitalizations for bronchiolitis in infants is not negligible. Respiratory syncytial virus is the etiologic agent identified and the cause of a higher number of admissions to intensive care. No deaths were observed.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: not found

          Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level.

          The risk for hospitalization with respiratory syncytial virus infection during the first year of life was about five per 1,000 live births per year for infants born to low-income families in Houston from 1975 to 1979. The risk varied depending upon the intensity of the epidemic for a given season, the month of birth of the infant, and the level of passively acquired maternal antibody at the time of birth. Over 80% of the children hospitalized were less than 6 months of age; thus, most were born during the six months preceding the peak of RS virus activity. The neutralizing antibody titers in cord sera of 68 infants with culture-proven infections before 6 months of age were significantly lower than those of 575 randomly selected cord samples of infants born during the same period. The level of antibody at the time of birth was directly correlated with age at the time of infection. In addition, infants with more severe illnesses had lower levels of antibody in serum collected near onset of illness than did infants with milder illnesses. These observations demonstrate protection against RS infection in early infancy that is correlated with the level of maternal antibody, but it is not known if this protection is mediated directly by the passively acquired antibody or by some other mechanism.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants

            Acute bronchiolitis is the leading cause of lower respiratory tract infection and hospitalization in children less than 1 year of age worldwide. It is usually a mild disease, but some children may develop severe symptoms, requiring hospital admission and ventilatory support in the ICU. Infants with pre-existing risk factors (prematurity, bronchopulmonary dysplasia, congenital heart diseases and immunodeficiency) may be predisposed to a severe form of the disease. Clinical diagnosis of bronchiolitis is manly based on medical history and physical examination (rhinorrhea, cough, crackles, wheezing and signs of respiratory distress). Etiological diagnosis, with antigen or genome detection to identify viruses involved, may have a role in reducing hospital transmission of the infection. Criteria for hospitalization include low oxygen saturation (<90-92%), moderate-to-severe respiratory distress, dehydration and presence of apnea. Children with pre-existing risk factors should be carefully assessed. To date, there is no specific treatment for viral bronchiolitis, and the mainstay of therapy is supportive care. This consists of nasal suctioning and nebulized 3% hypertonic saline, assisted feeding and hydration, humidified O2 delivery. The possible role of any pharmacological approach is still debated, and till now there is no evidence to support the use of bronchodilators, corticosteroids, chest physiotherapy, antibiotics or antivirals. Nebulized adrenaline may be sometimes useful in the emergency room. Nebulized adrenaline can be useful in the hospital setting for treatment as needed. Lacking a specific etiological treatment, prophylaxis and prevention, especially in children at high risk of severe infection, have a fundamental role. Environmental preventive measures minimize viral transmission in hospital, in the outpatient setting and at home. Pharmacological prophylaxis with palivizumab for RSV bronchiolitis is indicated in specific categories of children at risk during the epidemic period. Viral bronchiolitis, especially in the case of severe form, may correlate with an increased incidence of recurrent wheezing in pre-schooled children and with asthma at school age. The aim of this document is to provide a multidisciplinary update on the current recommendations for the management and prevention of bronchiolitis, in order to share useful indications, identify gaps in knowledge and drive future research.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Glucocorticoids for acute viral bronchiolitis in infants and young children.

              Previous systematic reviews have not shown clear benefit of glucocorticoids for acute viral bronchiolitis, but their use remains considerable. Recent large trials add substantially to current evidence and suggest novel glucocorticoid-including treatment approaches. To review the efficacy and safety of systemic and inhaled glucocorticoids in children with acute viral bronchiolitis. We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2012, Issue 12), MEDLINE (1950 to January week 2, 2013), EMBASE (1980 to January 2013), LILACS (1982 to January 2013), Scopus® (1823 to January 2013) and IRAN MedEx (1998 to November 2009). Randomised controlled trials (RCTs) comparing short-term systemic or inhaled glucocorticoids versus placebo or another intervention in children under 24 months with acute bronchiolitis (first episode with wheezing). Our primary outcomes were: admissions by days 1 and 7 for outpatient studies; and length of stay (LOS) for inpatient studies. Secondary outcomes included clinical severity parameters, healthcare use, pulmonary function, symptoms, quality of life and harms. Two authors independently extracted data on study and participant characteristics, interventions and outcomes. We assessed risk of bias and graded strength of evidence. We meta-analysed inpatient and outpatient results separately using random-effects models. We pre-specified subgroup analyses, including the combined use of bronchodilators used in a protocol. We included 17 trials (2596 participants); three had low overall risk of bias. Baseline severity, glucocorticoid schemes, comparators and outcomes were heterogeneous. Glucocorticoids did not significantly reduce outpatient admissions by days 1 and 7 when compared to placebo (pooled risk ratios (RRs) 0.92; 95% confidence interval (CI) 0.78 to 1.08 and 0.86; 95% CI 0.7 to 1.06, respectively). There was no benefit in LOS for inpatients (mean difference -0.18 days; 95% CI -0.39 to 0.04). Unadjusted results from a large factorial low risk of bias RCT found combined high-dose systemic dexamethasone and inhaled epinephrine reduced admissions by day 7 (baseline risk of admission 26%; RR 0.65; 95% CI 0.44 to 0.95; number needed to treat 11; 95% CI 7 to 76), with no differences in short-term adverse effects. No other comparisons showed relevant differences in primary outcomes. Current evidence does not support a clinically relevant effect of systemic or inhaled glucocorticoids on admissions or length of hospitalisation. Combined dexamethasone and epinephrine may reduce outpatient admissions, but results are exploratory and safety data limited. Future research should further assess the efficacy, harms and applicability of combined therapy.
                Bookmark

                Author and article information

                Contributors
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Journal
                adp
                Archivos de Pediatría del Uruguay
                Arch. Pediatr. Urug.
                Sociedad Uruguaya de Pediatría
                1688-1249
                December 2015
                : 86
                : 4
                : 2
                Affiliations
                [1 ] UDELAR
                Article
                S1688-12492015000400002
                62925285-e2b8-40f3-a864-7ca7e059131f

                http://creativecommons.org/licenses/by/4.0/

                History
                Product

                SciELO Uruguay

                Self URI (journal page): http://www.scielo.edu.uy/scielo.php?script=sci_serial&pid=1688-1249&lng=en
                Categories
                ANESTHESIOLOGY
                MEDICAL ETHICS
                MEDICINE, GENERAL & INTERNAL
                MEDICINE, LEGAL
                PEDIATRICS
                SURGERY

                Social law,General medicine,Pediatrics,Surgery,Anesthesiology & Pain management,Internal medicine
                BRONCHIOLITIS,INFANT NEWBORN,BRONQUIOLITIS,RECIÉN NACIDO

                Comments

                Comment on this article